Cataract Extraction Clinical Trial
Official title:
Contralateral Eye Comparison of Visual Outcomes and Patient Satisfaction After Routine Phacoemulsification and Implantation of ReSTOR and ReZoom IOLs
Verified date | July 2006 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cataract is prevalent throughout the world and IOLs are routinely implanted after the
extraction of the cataractous lens. It is the most frequently performed surgery in the United
States with an estimated 2-3 million procedures performed annually. With the aging population
on the rise, as well as the increasing popularity of refractive intraocular lenses, the
number of intraocular surgeries continues to rise. Over the years, the surgical technique has
evolved from intracapsular extraction to modern phacoemulsification. This development has
helped with the evolution of IOLs as well. The IOLs have advanced extensively: different
materials and designs are available, permitting implantation through smaller, sutureless
incisions. Traditional IOLs are of monofocal design providing vision at one distance,
typically far. Patients implanted with traditional monofocal IOLs usually require glasses for
near distance tasks such as reading. The new multifocal IOLs offer the possibility of seeing
well at more than one distance, without glasses or contacts.
The AcrySof ReSTOR (Alcon Laboratories) uses apodized diffractive technology — a design that
responds to how wide or small the eye's pupil might be — to provide near, intermediate, and
distance vision. Clinical studies used to support the March 2005 FDA approval showed that 80%
of people who received the lens did not use glasses for any activities after their cataract
surgery; 84% who received the lens in both eyes had distance vision of 20/25 or better, with
near vision of 20/32 or better.
ReZoom (Advanced Medical Optics) is a multifocal refractive zonal IOL that distributes light
over five optical zones to provide near, intermediate, and distance vision. The ReZoom is a
second-generation multifocal and was FDA-approved in March 2005. In a European study of 215
patients, 93% of ReZoom recipients reported never or only occasionally needing glasses. The
combined use of multifocal intraocular lenses is often a solution to best meet the patients'
refractive needs. There has been speculation that the implantation of ReSTOR in one eye and
ReZoom lens in the fellow eye can provide patients a larger range of useful vision in the
near range.
The purpose of this study is to evaluate visual outcome and patient satisfaction after
implantation of a diffractive multifocal IOL (ReSTOR) in one eye and a refractive multifocal
IOL (ReZoom) in the fellow eye after routine phacoemulsification and compare it to a control
group of patients implanted bilaterally with ReSTOR with both eyes targeted for 0 to ±0.25 D,
and to a group of patients implanted bilaterally with ReSTOR with the non-dominant eye
targeted for +1.00 D and the dominant eye targeted for 0 to +0.25 D.
Status | Completed |
Enrollment | 48 |
Est. completion date | August 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject must have an age-related cataract in both eyes. - 18 years of age or older. - Patient must desire cataract extraction. - Expected maximum of 4 weeks and minimum of 1 week interval between first and second eye surgeries. - Willing and able to comply with scheduled visits and other study procedures. Exclusion Criteria: - Preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphtalmus or macrophtalmus, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc. - Keratometric astigmatism exceeding 2.0 diopters. - Planned postoperative refraction for mono-vision. - Uncontrolled diabetes. - Use of any systemic or topical drug known to interfere with visual performance. - Contact lens use during the active treatment portion of the trial. - Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis. - Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control. - Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or study device implantation or may interfere with the interpretation of study results. - Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial. - Intraocular conventional surgery within the past three months or intraocular laser surgery within one month in the operated eye. - Other ocular surgery at the time of the cataract extraction. |
Country | Name | City | State |
---|---|---|---|
United States | Storm Eye Institute, Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00924729 -
Study of Ocular Penetration of Topically Administered Fluoroquinolones
|
Phase 4 | |
Completed |
NCT00565695 -
Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction
|
N/A | |
Completed |
NCT00524264 -
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
|
Phase 3 | |
Completed |
NCT00521456 -
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
|
Phase 3 | |
Completed |
NCT02973880 -
Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction
|
Phase 3 | |
Completed |
NCT00721695 -
Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00466908 -
Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery
|
||
Completed |
NCT00366665 -
Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems
|
N/A | |
Completed |
NCT05571683 -
Cerebral Oxymeter and End Tidal Carbondioxide Values Under Surgical Drapes With and Without Past COVID-19 Infection
|
||
Not yet recruiting |
NCT04977115 -
Clinical Evaluation of Intraocular Caliper-assisted Capsulotomy for Age-related Cataract
|
N/A | |
Withdrawn |
NCT00366613 -
Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation
|
Phase 4 | |
Completed |
NCT00366496 -
Surgical Outcomes After Routine Cataract Extraction & Implantation of a Conventional or Spheric Intraocular Lens
|
N/A | |
Not yet recruiting |
NCT03828500 -
Preoperative Fasting for Ambulatory Cataract Surgery: The PRACTICE Study
|
N/A | |
Completed |
NCT00842231 -
Assessment of Visual Performance in Patients With Low Levels of Astigmatism
|
N/A | |
Completed |
NCT00840580 -
Effect on Wound Healing of Vigamox Versus Cravit
|
Phase 4 | |
Completed |
NCT00851760 -
Epiretinal Macular Membrane and Cataract Extraction
|
N/A | |
Recruiting |
NCT03944070 -
Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
|
N/A | |
Completed |
NCT03364972 -
A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00
|
N/A | |
Completed |
NCT00824070 -
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
|
Phase 1 | |
Completed |
NCT00366691 -
Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
|
Phase 4 |